BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Youinou P, Renaudineau Y. The antiphospholipid syndrome as a model for B cell-induced autoimmune diseases. Thromb Res. 2004;114:363-369. [PMID: 15507266 DOI: 10.1016/j.thromres.2004.06.019] [Cited by in Crossref: 47] [Cited by in F6Publishing: 41] [Article Influence: 2.8] [Reference Citation Analysis]
Number Citing Articles
1 Costa R, Fazal S, Kaplan RB, Spero J, Costa R. Successful plasma exchange combined with rituximab therapy in aggressive APS-related cutaneous necrosis. Clin Rheumatol 2013;32:79-82. [DOI: 10.1007/s10067-010-1506-3] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
2 Khattri S, Zandman-goddard G, Peeva E. B-cell directed therapies in antiphospholipid antibody syndrome — New directions based on murine and human data. Autoimmunity Reviews 2012;11:717-22. [DOI: 10.1016/j.autrev.2011.12.011] [Cited by in Crossref: 46] [Cited by in F6Publishing: 36] [Article Influence: 4.6] [Reference Citation Analysis]
3 Dieudonné Y, Guffroy A, Poindron V, Sprauel PS, Martin T, Korganow AS, Gies V. B cells in primary antiphospholipid syndrome: Review and remaining challenges. Autoimmun Rev 2021;20:102798. [PMID: 33722752 DOI: 10.1016/j.autrev.2021.102798] [Reference Citation Analysis]
4 Bunch DO, McGregor JG, Khandoobhai NB, Aybar LT, Burkart ME, Hu Y, Hogan SL, Poulton CJ, Berg EA, Falk RJ, Nachman PH. Decreased CD5⁺ B cells in active ANCA vasculitis and relapse after rituximab. Clin J Am Soc Nephrol 2013;8:382-91. [PMID: 23293123 DOI: 10.2215/CJN.03950412] [Cited by in Crossref: 64] [Cited by in F6Publishing: 35] [Article Influence: 7.1] [Reference Citation Analysis]
5 George D, Erkan D. Antiphospholipid syndrome. Prog Cardiovasc Dis 2009;52:115-25. [PMID: 19732604 DOI: 10.1016/j.pcad.2009.06.005] [Cited by in Crossref: 43] [Cited by in F6Publishing: 30] [Article Influence: 3.3] [Reference Citation Analysis]
6 Long Y, Li W, Feng J, Ma Y, Sun Y, Xu L, Song Y, Liu C. Follicular helper and follicular regulatory T cell subset imbalance is associated with higher activated B cells and abnormal autoantibody production in primary anti-phospholipid syndrome patients. Clin Exp Immunol 2021. [PMID: 34309827 DOI: 10.1111/cei.13647] [Reference Citation Analysis]
7 Samudra AN, Dwyer KM, Selan C, Freddi S, Murray-Segal L, Nikpour M, Hickey MJ, Peter K, Robson SC, Sashindranath M, Cowan PJ, Nandurkar HH. CD39 and CD73 activity are protective in a mouse model of antiphospholipid antibody-induced miscarriages. J Autoimmun 2018;88:131-8. [PMID: 29103803 DOI: 10.1016/j.jaut.2017.10.009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
8 Carbone J, Gallego A, Lanio N, Navarro J, Orera M, Aguaron A, Fernandez-Cruz E, Sarmiento E. Quantitative abnormalities of peripheral blood distinct T, B, and natural killer cell subsets and clinical findings in obstetric antiphospholipid syndrome. J Rheumatol 2009;36:1217-25. [PMID: 19332638 DOI: 10.3899/jrheum.081079] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
9 Polese L, Boetto R, De Franchis G, Angriman I, Porzionato A, Norberto L, Sturniolo GC, Macchi V, De Caro R, Merigliano S. B1a lymphocytes in the rectal mucosa of ulcerative colitis patients. World J Gastroenterol 2012; 18(2): 144-149 [PMID: 22253520 DOI: 10.3748/wjg.v18.i2.144] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
10 Božič B, Čučnik S, Kveder T, Rozman B. Avidity of anti-beta-2-glycoprotein I antibodies. Autoimmunity Reviews 2005;4:303-8. [DOI: 10.1016/j.autrev.2005.01.001] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.2] [Reference Citation Analysis]
11 Yazici A, Yazirli B, Erkan D. Belimumab in primary antiphospholipid syndrome. Lupus 2017;26:1123-4. [PMID: 27913749 DOI: 10.1177/0961203316682102] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
12 Erkan D, Vega J, Ramón G, Kozora E, Lockshin MD. A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome. Arthritis & Rheumatism 2013;65:464-71. [DOI: 10.1002/art.37759] [Cited by in Crossref: 179] [Cited by in F6Publishing: 131] [Article Influence: 19.9] [Reference Citation Analysis]
13 Sung N, Byeon H, Garcia MS, Skariah A, Wu L, Dambaeva S, Beaman K, Gilman-sachs A, Kwak-kim J. Deficiency in memory B cell compartment in a patient with infertility and recurrent pregnancy losses. Journal of Reproductive Immunology 2016;118:70-5. [DOI: 10.1016/j.jri.2016.09.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
14 Rodríguez-Pintó I, Cervera R, Espinosa G. Rituximab and its therapeutic potential in catastrophic antiphospolipid syndrome. Ther Adv Musculoskelet Dis 2015;7:26-30. [PMID: 25649844 DOI: 10.1177/1759720X14554793] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
15 Polese L, De Franchis G, Scarpa M, Sturniolo GC, Ruffolo C, Norberto L, Frego M, D'Amico DF, Angriman I. B1a lymphocytes in ulcerative colitis. Int J Colorectal Dis. 2007;22:1005-1011. [PMID: 17372743 DOI: 10.1007/s00384-007-0298-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
16 Bettacchioli E, Nafai S, Renaudineau Y. News and meta-analysis regarding anti-Beta 2 glycoprotein I antibodies and their determination. Clinical Immunology 2019;205:106-15. [DOI: 10.1016/j.clim.2019.06.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
17 Erkan D, Aguiar CL, Andrade D, Cohen H, Cuadrado MJ, Danowski A, Levy RA, Ortel TL, Rahman A, Salmon JE, Tektonidou MG, Willis R, Lockshin MD. 14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends. Autoimmun Rev. 2014;13:685-696. [PMID: 24468415 DOI: 10.1016/j.autrev.2014.01.053] [Cited by in Crossref: 230] [Cited by in F6Publishing: 182] [Article Influence: 28.8] [Reference Citation Analysis]
18 Abisror N, Mekinian A, Brechignac S, Ruffatti A, Carbillon L, Fain O. Inefficacy of plasma exchanges associated to rituximab in refractory obstetrical antiphospholipid syndrome. Presse Med 2015;44:100-2. [PMID: 25488712 DOI: 10.1016/j.lpm.2014.05.021] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
19 Cervera R, Espinosa G. Antiphospholipid syndrome: long-time research on pathogenic mechanisms has finally lead to new therapeutic strategies. Expert Opinion on Therapeutic Targets 2010;14:1279-82. [DOI: 10.1517/14728222.2010.530900] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
20 Rückert A, Glimm H, Lübbert M, Grüllich C. Successful treatment of life-threatening Evans syndrome due to antiphospholipid antibody syndrome by rituximab-based regimen: a case with long-term follow-up. Lupus 2008;17:757-60. [PMID: 18625656 DOI: 10.1177/0961203307087876] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
21 Arkfeld DG. The potential utility of B cell-directed biologic therapy in autoimmune diseases. Rheumatol Int 2008;28:205-15. [PMID: 17957371 DOI: 10.1007/s00296-007-0471-x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 2.0] [Reference Citation Analysis]
22 d'Arbonneau F, Pers J, Devauchelle V, Pennec Y, Saraux A, Youinou P. BAFF-induced changes in B cell antigen receptor–containing lipid rafts in Sjögren's syndrome. Arthritis Rheum 2006;54:115-26. [DOI: 10.1002/art.21478] [Cited by in Crossref: 60] [Cited by in F6Publishing: 51] [Article Influence: 3.5] [Reference Citation Analysis]
23 Berman H, Rodríguez-pintó I, Cervera R, Morel N, Costedoat-chalumeau N, Erkan D, Shoenfeld Y, Espinosa G. Rituximab use in the catastrophic antiphospholipid syndrome: Descriptive analysis of the CAPS registry patients receiving rituximab. Autoimmunity Reviews 2013;12:1085-90. [DOI: 10.1016/j.autrev.2013.05.004] [Cited by in Crossref: 150] [Cited by in F6Publishing: 108] [Article Influence: 16.7] [Reference Citation Analysis]
24 Sevim E, Willis R, Erkan D. Is there a role for immunosuppression in antiphospholipid syndrome? Hematology Am Soc Hematol Educ Program 2019;2019:426-32. [PMID: 31808842 DOI: 10.1182/hematology.2019000073] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
25 Pierangeli S, Erkan D. Antiphospholipid syndrome treatment beyond anticoagulation: are we there yet? Lupus 2010;19:475-85. [DOI: 10.1177/0961203310361489] [Cited by in Crossref: 41] [Cited by in F6Publishing: 33] [Article Influence: 3.4] [Reference Citation Analysis]
26 Erkan D, Lockshin MD. New approaches for managing antiphospholipid syndrome. Nat Rev Rheumatol 2009;5:160-70. [DOI: 10.1038/ncprheum1017] [Cited by in Crossref: 41] [Cited by in F6Publishing: 31] [Article Influence: 3.2] [Reference Citation Analysis]
27 Alvarez-Rodriguez L, Riancho-Zarrabeitia L, Calvo-Alén J, López-Hoyos M, Martínez-Taboada V. Peripheral B-Cell Subset Distribution in Primary Antiphospholipid Syndrome. Int J Mol Sci 2018;19:E589. [PMID: 29462939 DOI: 10.3390/ijms19020589] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
28 D'Angelo C, Franch O, Fernández-Paredes L, Oreja-Guevara C, Núñez-Beltrán M, Comins-Boo A, Reale M, Sánchez-Ramón S. Antiphospholipid Antibodies Overlapping in Isolated Neurological Syndrome and Multiple Sclerosis: Neurobiological Insights and Diagnostic Challenges. Front Cell Neurosci 2019;13:107. [PMID: 30941020 DOI: 10.3389/fncel.2019.00107] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
29 Lackner KJ, Müller-Calleja N. Antiphospholipid Antibodies: Their Origin and Development. Antibodies (Basel) 2016;5:E15. [PMID: 31557996 DOI: 10.3390/antib5020015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
30 Erkan D, Lockshin M. Non-criteria manifestations of antiphospholipid syndrome. Lupus 2010;19:424-7. [DOI: 10.1177/0961203309360545] [Cited by in Crossref: 45] [Cited by in F6Publishing: 36] [Article Influence: 3.8] [Reference Citation Analysis]
31 Papalardo E, Romay-Penabad Z, Willis R, Christadoss P, Carrera-Marin AL, Reyes-Maldonado E, Rudrangi R, Alfieri-Papalardo S, Garcia-Latorre E, Blank M, Pierangeli S, Brasier AR, Gonzalez EB. Major Histocompatibility Complex Class II Alleles Influence Induction of Pathogenic Antiphospholipid Antibodies in a Mouse Model of Thrombosis. Arthritis Rheumatol 2017;69:2052-61. [PMID: 28666081 DOI: 10.1002/art.40195] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
32 Mehdi AA, Uthman I, Khamashta M. Antiphospholipid syndrome: pathogenesis and a window of treatment opportunities in the future. European Journal of Clinical Investigation 2010;40:451-64. [DOI: 10.1111/j.1365-2362.2010.02281.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 2.2] [Reference Citation Analysis]
33 Dierickx D, Beke E, Devos T, Delannoy A. The Use of Monoclonal Antibodies in Immune-Mediated Hematologic Disorders. Medical Clinics of North America 2012;96:583-619. [DOI: 10.1016/j.mcna.2012.04.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
34 Paulson JC, Macauley MS, Kawasaki N. Siglecs as sensors of self in innate and adaptive immune responses. Ann N Y Acad Sci 2012;1253:37-48. [PMID: 22288608 DOI: 10.1111/j.1749-6632.2011.06362.x] [Cited by in Crossref: 67] [Cited by in F6Publishing: 63] [Article Influence: 6.7] [Reference Citation Analysis]
35 Salma N, Julie L, Boutahar B, Sylvie LN, Eleonore B, Fabien LN, Elisabeth P, Sandrine JJ, Francis C, Sophie H, Yves R. Thrombotic risk assessment and analytical performance of the chemiluminescent analyzer IDS-iSYS for the detection of anti-cardiolipin and anti-beta 2 glycoprotein I autoantibodies. Clin Immunol 2018;194:92-9. [PMID: 30017909 DOI: 10.1016/j.clim.2018.07.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
36 Gracia-Tello B, Isenberg D. Kidney disease in primary anti-phospholipid antibody syndrome. Rheumatology (Oxford) 2017;56:1069-80. [PMID: 27550302 DOI: 10.1093/rheumatology/kew307] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
37 Ortiz-Fernández L, Sawalha AH. Genetics of Antiphospholipid Syndrome. Curr Rheumatol Rep 2019;21:65. [PMID: 31807905 DOI: 10.1007/s11926-019-0869-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
38 Ames PRJ, Tommasino C, Fossati G, Scenna G, Brancaccio V, Ferrara F. Limited effect of rituximab on thrombocytopaenia and anticardiolipin antibodies in a patient with primary antiphospholipid syndrome. Ann Hematol 2007;86:227-8. [DOI: 10.1007/s00277-006-0226-x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
39 Ota K, Dambaeva S, Lee J, Gilman-sachs A, Beaman K, Kwak-kim J. Persistent High Levels of IgM Antiphospholipid Antibodies in a Patient with Recurrent Pregnancy Losses and Rheumatoid Arthritis. Am J Reprod Immunol 2014;71:286-92. [DOI: 10.1111/aji.12196] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
40 Lopez-Pedrera Ch, Aguirre MA, Ruiz-Limon P, Pérez-Sánchez C, Jimenez-Gomez Y, Barbarroja N, Cuadrado MJ. Immunotherapy in antiphospholipid syndrome. Int Immunopharmacol 2015;27:200-8. [PMID: 26086363 DOI: 10.1016/j.intimp.2015.06.006] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
41 Simonin L, Pasquier E, Leroyer C, Cornec D, Lemerle J, Bendaoud B, Hillion S, Pers JO, Couturaud F, Renaudineau Y. Lymphocyte Disturbances in Primary Antiphospholipid Syndrome and Application to Venous Thromboembolism Follow-Up. Clin Rev Allergy Immunol 2017;53:14-27. [PMID: 27342459 DOI: 10.1007/s12016-016-8568-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]